Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt IssuancesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibrx Biosciences (INBX) Net Income (2023 - 2025)

Historic Net Income for Inhibrx Biosciences (INBX) over the last 3 years, with Q3 2025 value amounting to -$35.3 million.

  • Inhibrx Biosciences' Net Income rose 1962.43% to -$35.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$155.1 million, marking a year-over-year decrease of 10943.65%. This contributed to the annual value of $1.7 billion for FY2024, which is 80395.57% up from last year.
  • Latest data reveals that Inhibrx Biosciences reported Net Income of -$35.3 million as of Q3 2025, which was up 1962.43% from -$28.7 million recorded in Q2 2025.
  • In the past 5 years, Inhibrx Biosciences' Net Income ranged from a high of $1.9 billion in Q2 2024 and a low of -$92.0 million during Q4 2023
  • For the 3-year period, Inhibrx Biosciences' Net Income averaged around $139.0 million, with its median value being -$45.5 million (2023).
  • Per our database at Business Quant, Inhibrx Biosciences' Net Income surged by 404884.6% in 2024 and then plummeted by 10154.22% in 2025.
  • Inhibrx Biosciences' Net Income (Quarter) stood at -$92.0 million in 2023, then soared by 47.96% to -$47.9 million in 2024, then grew by 26.34% to -$35.3 million in 2025.
  • Its Net Income was -$35.3 million in Q3 2025, compared to -$28.7 million in Q2 2025 and -$43.3 million in Q1 2025.